Pharmacological overview of the BGP-15 chemical agent as a new drug candidate for the treatment of symptoms of metabolic syndrome

Ágota Pető, Dóra Kósa, Pálma Fehér, Zoltán Ujhelyi, Dávid Sinka, Miklós Vecsernyés, Zoltán Szilvássy, Béla Juhász, Zoltán Csanádi, László Vígh, Ildikó Bácskay

Research output: Contribution to journalReview article

Abstract

BGP-15 is a new insulin sensitizer drug candidate, which was developed by Hungarian researchers. In recent years, numerous research groups have studied its beneficial effects. It is effective in the treatment of insulin resistance and it has protective effects in Duchenne muscular dystrophy, diastolic dysfunction, tachycardia, heart failure, and atrial fibrillation, and it can alleviate cardiotoxicity. BGP-15 exhibits chemoprotective properties in different cytostatic therapies, and has also proven to be photoprotective. It can additionally have advantageous effects in mitochondrial-stress-related diseases. Although the precise mechanism of the effect is still unknown to us, we know that the molecule is a PARP inhibitor, chaperone co-inducer, reduces ROS production, and is able to remodel the organization of cholesterol-rich membrane domains. In the following review, our aim was to summarize the investigated molecular mechanisms and pharmacological effects of this potential API. The main objective was to present the wide pharmacological potentials of this chemical agent.

Original languageEnglish
Article number429
JournalMolecules
Volume25
Issue number2
DOIs
Publication statusPublished - Jan 20 2020

Keywords

  • BGP-15
  • Chaperone co-inducer
  • Insulin sensitizer
  • PARP inhibitor

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Pharmacological overview of the BGP-15 chemical agent as a new drug candidate for the treatment of symptoms of metabolic syndrome'. Together they form a unique fingerprint.

  • Cite this

    Pető, Á., Kósa, D., Fehér, P., Ujhelyi, Z., Sinka, D., Vecsernyés, M., Szilvássy, Z., Juhász, B., Csanádi, Z., Vígh, L., & Bácskay, I. (2020). Pharmacological overview of the BGP-15 chemical agent as a new drug candidate for the treatment of symptoms of metabolic syndrome. Molecules, 25(2), [429]. https://doi.org/10.3390/molecules25020429